Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Ibrutinib Capsules 140mg
IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Ibrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down and control the growth of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists for the management of chronic blood-related malignancies and advanced lymphoma conditions.
Ibrutinib works by targeting specific proteins responsible for the growth and survival of cancer cells. By blocking BTK activity, the medicine interferes with cancer cell signaling pathways and helps reduce the spread of abnormal B-cells. Due to its targeted mechanism of action, IBRULIEVA 140 MG has become an important medicine in modern hematology-oncology treatment protocols.
This targeted therapy capsule is widely used in the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Chronic Graft Versus Host Disease (cGVHD)
Doctors may prescribe IBRULIEVA alone or in combination with other oncology medicines depending on the patient’s medical condition, stage of cancer, treatment history, and response to therapy.
IBRULIEVA 140 MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended strictly for medical use and should only be taken under the supervision of qualified healthcare professionals.
Blood cancers and lymphatic malignancies can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted cancer therapies like Ibrutinib help improve disease management by specifically targeting cancer-related pathways without affecting healthy cells as extensively as traditional chemotherapy.
Patients receiving IBRULIEVA 140 MG may require regular blood tests, medical monitoring, and health assessments during treatment to help manage side effects and improve treatment outcomes. Doctors carefully determine dosage and treatment duration based on the patient’s overall condition and treatment goals.
Due to its effectiveness in targeted cancer treatment and hematology care, IBRULIEVA 140 MG is widely used in hospitals, oncology centers, hematology clinics, and advanced cancer treatment programs.
View Details
Melphalan Tablet IP 2mg
MELIEVA 2 MG (Melphalan Tablet IP 2 mg) is an anticancer chemotherapy medicine used in the treatment and management of multiple myeloma, ovarian cancer, and certain other cancer-related conditions. It contains Melphalan, a well-known alkylating agent that helps destroy cancer cells by interfering with their DNA and preventing them from multiplying inside the body.
Melphalan is widely used in oncology and hematology treatment programs because of its effectiveness in slowing the growth and spread of abnormal cancer cells. This medicine is commonly prescribed by oncologists as part of chemotherapy treatment protocols for patients requiring long-term cancer management and supportive oncology care.
Cancer cells grow and divide rapidly, affecting normal body functions and overall health. MELIEVA 2 MG works by damaging the genetic material of cancer cells, which reduces their ability to survive and reproduce. This targeted effect helps control cancer progression and supports modern chemotherapy treatment strategies.
MELIEVA 2 MG is mainly used in:
• Multiple myeloma treatment
• Ovarian cancer management
• Bone marrow-related cancer conditions
• Advanced oncology treatment programs
• Certain hematological disorders under specialist supervision
This anticancer medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology treatment.
Doctors may prescribe MELIEVA alone or in combination with other chemotherapy medicines depending on the patient’s medical condition, cancer type, stage of disease, and response to therapy.
Patients receiving Melphalan therapy may require regular blood tests, bone marrow monitoring, liver function assessments, and medical evaluations during treatment. Chemotherapy medicines can affect healthy cells along with cancer cells, so close medical supervision is important for improving treatment outcomes and reducing complications.
Due to its effectiveness in oncology and hematology care, MELIEVA 2 MG has become an important medicine in cancer treatment protocols and long-term chemotherapy management programs.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Acalabrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down the growth and spread of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists as part of advanced cancer treatment protocols for chronic blood-related malignancies.
Acalabrutinib works by blocking the activity of BTK proteins that are involved in the growth and survival of cancerous B-cells. By interrupting these cancer cell signaling pathways, ACALIEVA 100MG helps reduce the multiplication and survival of abnormal cells, supporting long-term cancer management and disease control.
This targeted therapy medicine is widely used in modern hematology-oncology treatment because of its precision-based mechanism and effectiveness in managing blood cancers with fewer effects on healthy cells compared to some traditional chemotherapy medicines.
ACALIEVA 100MG is mainly prescribed for the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Certain relapsed or refractory blood cancers
• Advanced hematology-oncology treatment programs
Doctors may prescribe Acalabrutinib Capsules alone or in combination with other anticancer medicines depending on the patient’s condition, stage of disease, previous treatment history, and response to therapy.
Blood cancers can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted therapy medicines like Acalabrutinib help control cancer progression by specifically targeting cancer-related proteins responsible for abnormal B-cell growth.
ACALIEVA 100MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.
Patients undergoing treatment with ACALIEVA may require regular blood tests, medical monitoring, infection screening, and overall health assessments during therapy. Proper monitoring helps improve treatment effectiveness and reduce the risk of complications or serious side effects.
Due to its effectiveness in targeted cancer therapy and hematology care, ACALIEVA 100MG has become an important medicine in modern oncology treatment protocols and long-term blood cancer management programs.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA 500MG (Hydroxyurea Capsules IP 500mg) is a prescription medicine used in the treatment of certain blood disorders and cancers. It contains Hydroxyurea 500mg, a well-established antimetabolite medication that works by slowing the growth and multiplication of abnormal cells in the body. Hydroxyurea is widely prescribed by hematologists and oncologists for managing conditions such as chronic myeloid leukemia, sickle cell disease, and other myeloproliferative disorders.
HYDLIEVA 500MG plays an important role in modern hematology and oncology treatment because it helps control excessive blood cell production and reduces disease-related complications. The medicine works by interfering with DNA synthesis, which slows down the growth of rapidly dividing cells. This mechanism makes Hydroxyurea effective in managing both cancerous and non-cancerous blood disorders.
Patients with blood-related conditions often require long-term treatment and careful monitoring. HYDLIEVA 500MG helps improve disease control, reduce complications, and support overall quality of life when used under appropriate medical supervision.
This medicine is commonly prescribed for:
• Chronic Myeloid Leukemia (CML)
• Sickle Cell Disease
• Polycythemia Vera
• Essential Thrombocythemia
• Certain Myeloproliferative Disorders
• Blood Cell Production Disorders
• Hematology and Oncology Treatment Programs
Hydroxyurea has been widely used for many years and remains an important treatment option in specialized blood disorder management. It is particularly valuable in sickle cell disease, where it helps reduce painful crises and improve overall disease outcomes.
HYDLIEVA 500MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals.
Patients receiving Hydroxyurea therapy may require regular blood tests, kidney function monitoring, liver function assessments, and medical evaluations throughout treatment. These assessments help ensure treatment effectiveness and identify potential side effects early.
Due to its proven effectiveness in hematology and oncology care, HYDLIEVA 500MG remains an important medicine in modern blood disorder treatment programs.
View Details
Imatinib Mesylate Tablets IP 400mg
IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) is a targeted anticancer medicine used for the treatment of certain blood cancers, gastrointestinal tumors, and other cancers driven by specific genetic abnormalities. It contains Imatinib Mesylate 400 mg, a tyrosine kinase inhibitor (TKI) that works by blocking abnormal proteins responsible for the growth and multiplication of cancer cells.
Imatinib revolutionized cancer treatment by becoming one of the first successful targeted therapies. Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Imatinib specifically targets abnormal enzymes that contribute to cancer progression. This targeted approach helps slow disease progression, improve treatment outcomes, and support long-term cancer management.
IMALIEVA 400 MG is widely prescribed by oncologists and hematologists for patients diagnosed with specific cancers that contain abnormal tyrosine kinase activity. By targeting these cancer-driving proteins, the medicine helps control tumor growth and reduce the spread of disease.
This medicine is commonly used in the treatment of:
• Chronic Myeloid Leukemia (CML)
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative Disorders (MDS/MPD)
• Hypereosinophilic Syndrome (HES)
• Dermatofibrosarcoma Protuberans (DFSP)
• Advanced Hematological and Solid Tumor Conditions
IMALIEVA 400 MG may be prescribed as a first-line treatment or as part of long-term cancer management programs depending on the patient's diagnosis, treatment history, and response to therapy.
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving Imatinib therapy may require regular blood tests, liver function monitoring, kidney assessments, and periodic medical evaluations to ensure optimal treatment outcomes and early detection of potential side effects.
Due to its proven effectiveness in targeted cancer therapy, IMALIEVA 400 MG has become one of the most important medicines in modern oncology and hematology treatment programs worldwide.
View Details
Azacitidine for Injection 100MG
AZALIEVA 100 MG (Azacitidine for Injection 100 mg) is a prescription anticancer medicine used for the treatment of certain blood and bone marrow disorders, including Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), and related hematological conditions. It contains Azacitidine 100 mg, a hypomethylating agent that helps restore normal bone marrow function and slows the growth of abnormal blood cells.
Blood and bone marrow disorders occur when the bone marrow produces abnormal or immature blood cells that fail to function properly. These abnormal cells can crowd out healthy blood cells, leading to complications such as anemia, infections, bleeding disorders, and progression to leukemia. AZALIEVA 100 MG helps improve blood cell production by targeting abnormal cellular processes involved in disease progression.
Azacitidine works by affecting DNA methylation and gene expression within abnormal cells. By modifying these cellular mechanisms, the medicine helps normalize bone marrow activity, reduce the number of abnormal cells, and support the production of healthy blood cells. This approach can help improve blood counts, reduce transfusion requirements, and enhance overall treatment outcomes.
AZALIEVA 100 MG is commonly prescribed for:
• Myelodysplastic Syndromes (MDS)
• Acute Myeloid Leukemia (AML)
• Chronic Myelomonocytic Leukemia (CMML)
• Bone Marrow Disorders
• Hematological Malignancies
• High-Risk Blood Disorders
• Oncology and Hematology Treatment Programs
• Long-Term Disease Management
The medicine may be used as a standalone treatment or as part of a comprehensive hematology care plan depending on the patient's diagnosis, disease stage, and overall health condition.
Manufactured under strict pharmaceutical quality standards, AZALIEVA 100 MG is designed to provide consistent therapeutic performance, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Azacitidine therapy often require routine blood tests, bone marrow evaluations, liver function monitoring, kidney assessments, and regular medical follow-ups to monitor treatment effectiveness and manage potential side effects.
Due to its established role in treating serious blood disorders and improving bone marrow function, AZALIEVA 100 MG remains an important medicine in modern hematology and oncology care.
View Details
Plerixafor Injection 24mg
MOZOLIEVA 24 MG (Plerixafor Injection 24 mg) is a prescription hematology medicine used to help mobilize hematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous stem cell transplantation. It contains Plerixafor 24 mg, a selective CXCR4 chemokine receptor antagonist that plays a crucial role in stem cell mobilization for patients undergoing treatment for certain blood cancers and hematological disorders.
Stem cell transplantation is an important treatment option for patients with conditions such as Multiple Myeloma and Non-Hodgkin Lymphoma. Before transplantation can take place, a sufficient number of healthy stem cells must be collected from the patient's bloodstream. In some patients, collecting an adequate number of stem cells can be challenging. MOZOLIEVA 24 MG helps overcome this challenge by increasing the release of stem cells from the bone marrow into the circulation, making collection more efficient.
Plerixafor works by blocking the interaction between the CXCR4 receptor and its natural ligand, stromal cell-derived factor-1 (SDF-1). This disruption allows stem cells to move from the bone marrow into the bloodstream, where they can be collected through a process called apheresis.
MOZOLIEVA 24 MG is commonly used for:
• Stem Cell Mobilization
• Autologous Stem Cell Transplantation
• Multiple Myeloma Treatment Programs
• Non-Hodgkin Lymphoma Treatment Programs
• Hematopoietic Stem Cell Collection
• Bone Marrow Supportive Care
• Advanced Hematology Treatment Protocols
• Specialized Oncology and Transplant Centers
The medicine is generally administered in combination with Granulocyte Colony-Stimulating Factor (G-CSF) to enhance stem cell mobilization and improve collection success rates.
Manufactured under strict pharmaceutical quality standards, MOZOLIEVA 24 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in hematology, oncology, and stem cell transplantation procedures.
Patients receiving Plerixafor therapy may require regular blood count monitoring, stem cell collection assessments, and medical supervision to ensure effective mobilization and optimal transplant preparation.
Due to its effectiveness in improving stem cell collection, MOZOLIEVA 24 MG has become an important supportive medicine in modern hematology and transplant medicine.
View Details
Fludarabine Phosphate for Injection 50mg
FLULIEVA 50 MG (Fludarabine Phosphate for Injection 50 mg) is a prescription anticancer medicine used for the treatment of certain blood cancers and hematological disorders, particularly Chronic Lymphocytic Leukemia (CLL) and selected lymphoproliferative conditions. It contains Fludarabine Phosphate 50 mg, a chemotherapy medicine that belongs to the class of drugs known as purine analog antimetabolites. The medicine works by interfering with the growth and multiplication of abnormal cancer cells, helping to slow disease progression and improve treatment outcomes.
Blood cancers occur when abnormal white blood cells grow uncontrollably and accumulate in the blood, bone marrow, lymph nodes, or other organs. These abnormal cells interfere with the body's ability to produce healthy blood cells and fight infections effectively. FLULIEVA 50 MG targets these cancerous cells by disrupting DNA synthesis, preventing them from multiplying and surviving.
Fludarabine has become an important medicine in modern hematology and oncology because of its effectiveness in treating specific leukemias and lymphoid malignancies. It is often used alone or in combination with other anticancer medicines as part of specialized treatment protocols.
FLULIEVA 50 MG is commonly prescribed for:
Chronic Lymphocytic Leukemia (CLL)
B-Cell Chronic Lymphocytic Leukemia
Low-Grade Non-Hodgkin Lymphoma
Indolent Lymphoid Malignancies
Hematological Cancers
Relapsed or Refractory Blood Cancers
Combination Chemotherapy Programs
Advanced Hematology Treatment Protocols
The medicine may be recommended when patients require systemic therapy to control disease progression or when previous treatments have not provided adequate results.
Manufactured under strict pharmaceutical quality standards, FLULIEVA 50 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, and specialized hematology treatment facilities.
Patients receiving Fludarabine therapy often require routine blood tests, immune system monitoring, kidney function assessments, and regular medical evaluations to ensure treatment effectiveness and minimize potential risks.
Due to its established role in treating blood cancers, FLULIEVA 50 MG remains an important component of modern leukemia and lymphoma management programs worldwide.
View Details
Methotrexate Injection 500mg
TREXLIEVA 500 MG (Methotrexate Injection 500 mg) is a prescription medicine containing Methotrexate 500 mg, a widely used antimetabolite and antifolate agent utilized in the treatment of various cancers, autoimmune disorders, and certain severe inflammatory conditions. In oncology, Methotrexate plays a critical role in controlling the growth and spread of rapidly dividing cancer cells by interfering with DNA synthesis and cellular replication.
Methotrexate has been an important component of cancer treatment protocols for several decades and is used in hospitals and specialized oncology centers worldwide. It is commonly prescribed for cancers such as Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Osteosarcoma, Breast Cancer, Head and Neck Cancer, and certain other malignancies. The medicine may also be used in selected non-cancer conditions under strict medical supervision.
Cancer cells multiply rapidly and require folic acid to produce DNA and grow. TREXLIEVA 500 MG works by blocking the enzyme Dihydrofolate Reductase (DHFR), which is essential for folic acid metabolism. By disrupting this process, Methotrexate prevents cancer cells from producing the DNA necessary for growth and division, ultimately leading to cell death.
TREXLIEVA 500 MG is commonly used for:
Acute Lymphoblastic Leukemia (ALL)
Non-Hodgkin Lymphoma
Osteosarcoma
Breast Cancer
Head and Neck Cancer
Gestational Trophoblastic Neoplasia
Central Nervous System Prophylaxis in Leukemia
Combination Chemotherapy Programs
Advanced Oncology Treatment Protocols
The medicine may be administered alone or in combination with other anticancer medicines depending on the type of cancer, disease stage, and treatment goals. High-dose Methotrexate therapy is often followed by specialized supportive care measures, including leucovorin rescue, to help reduce toxicity.
Manufactured under strict pharmaceutical quality standards, TREXLIEVA 500 MG is designed to provide consistent therapeutic performance, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.
Patients receiving Methotrexate therapy typically require regular monitoring through blood tests, liver function assessments, kidney function evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and broad therapeutic applications, TREXLIEVA 500 MG remains an essential medicine in modern oncology and specialized medical care.
View Details
Methotrexate Injection IP 50mg
TREXLIEVA 50 MG (Methotrexate Injection IP 50 mg) is a prescription medicine containing Methotrexate 50 mg, a widely used antimetabolite and antifolate agent utilized in the treatment of various cancers, autoimmune disorders, and certain severe inflammatory conditions. In oncology, Methotrexate plays a crucial role in controlling the growth and spread of rapidly dividing cancer cells by interfering with DNA synthesis and cell replication.
Methotrexate has been a cornerstone of cancer treatment for decades and is commonly used in hospitals, oncology centers, and specialized healthcare facilities worldwide. The medicine is prescribed for the management of cancers such as Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Breast Cancer, Head and Neck Cancer, Gestational Trophoblastic Disease, and various other malignancies. It may also be used for selected non-cancer medical conditions under specialist supervision.
Cancer cells require folic acid to produce DNA and multiply. TREXLIEVA 50 MG works by inhibiting the enzyme Dihydrofolate Reductase (DHFR), which is essential for folic acid metabolism. By blocking this enzyme, Methotrexate prevents cancer cells from producing the DNA necessary for growth and division, ultimately slowing disease progression and promoting cancer cell death.
TREXLIEVA 50 MG is commonly prescribed for:
Acute Lymphoblastic Leukemia (ALL)
Non-Hodgkin Lymphoma
Breast Cancer
Head and Neck Cancer
Gestational Trophoblastic Disease
Certain Bone and Soft Tissue Cancers
Combination Chemotherapy Programs
Advanced Oncology Treatment Protocols
The medicine may be administered alone or in combination with other anticancer agents depending on the type of cancer, disease stage, and treatment objectives.
Manufactured under stringent pharmaceutical quality standards, TREXLIEVA 50 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.
Patients receiving Methotrexate therapy often require regular blood tests, liver function assessments, kidney function evaluations, and routine clinical monitoring to ensure safe and effective treatment outcomes.
Due to its established efficacy and broad therapeutic applications, TREXLIEVA 50 MG remains an important medicine in modern oncology and specialized medical care.
View Details
Bortezomib Injection IP 3.5mg
BORTELIEVA 3.5 MG (Bortezomib Injection IP 3.5 mg) is a prescription anticancer medicine containing Bortezomib 3.5 mg, a targeted therapy used primarily for the treatment of Multiple Myeloma and Mantle Cell Lymphoma (MCL). Bortezomib belongs to a class of medicines known as proteasome inhibitors, which work by disrupting important cellular processes within cancer cells, leading to their destruction while helping slow disease progression.
Multiple Myeloma is a type of blood cancer that develops in plasma cells, a specialized type of white blood cell responsible for producing antibodies. When these cells become cancerous, they multiply uncontrollably and can damage bones, kidneys, and the immune system. Mantle Cell Lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that affects lymphocytes within the lymphatic system. BORTELIEVA 3.5 MG is designed to target these abnormal cancer cells and help improve treatment outcomes.
Bortezomib works by blocking proteasomes, which are structures inside cells responsible for breaking down unwanted proteins. Cancer cells depend heavily on proteasomes for survival and rapid growth. When proteasome activity is inhibited, damaged proteins accumulate within cancer cells, triggering stress and ultimately causing cell death. This targeted mechanism makes Bortezomib an important therapy in modern hematology and oncology practice.
BORTELIEVA 3.5 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Mantle Cell Lymphoma (MCL)
Recurrent Hematological Malignancies
Combination Chemotherapy and Targeted Therapy Protocols
Advanced Blood Cancer Treatment Programs
Specialized Oncology and Hematology Care
The medicine may be administered alone or in combination with other anticancer agents depending on the patient's condition, treatment history, and therapeutic goals.
Manufactured under stringent pharmaceutical quality standards, BORTELIEVA 3.5 MG is designed to deliver consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bortezomib therapy often require routine blood tests, liver function monitoring, kidney assessments, neurological evaluations, and regular clinical follow-up to ensure safe and effective treatment.
Due to its proven efficacy in blood cancer treatment, BORTELIEVA 3.5 MG remains an essential medicine in modern oncology care worldwide.
View Details
